Merck & Co. Forms Bispecific Antibody Collaboration with Zymeworks
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)
Published: 19 Sep-2011
DOI: 10.3833/pdr.v2011.i9.1545 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Zymeworks has signed its first major deal, a US$187 M global licensing agreement with Merck & Co...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS